Inclusion Criteria:

          -  Male or female subjects, age 18 years or older

          -  Subjects with histologically or cytologically confirmed NSCLC, MEL (including I/O
             relapsed MEL or I/O refractory MEL), CRC, SCCHN, ovarian cancer, recurrent B cell NHL
             or HL, or glioblastoma

          -  Presence of measurable disease by RECIST v1.1 for solid tumors or Cheson criteria for
             B cell NHL (including DLBCL) or HL. For subjects with glioblastoma, presence of
             measurable disease is not required.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

          -  Fresh baseline tumor biopsies (defined as a biopsy specimen taken since completion of
             the most recent prior chemotherapy regimen) are required for all cohorts except
             glioblastoma

        Exclusion Criteria:

          -  Laboratory and medical history parameters not within Protocol-defined range

          -  Currently pregnant or breastfeeding

          -  Subjects who have received prior immune checkpoint inhibitors or an IDO inhibitor
             (except select Phase 2 cohorts evaluating I/O relapsed or I/O refractory MEL).
             Subjects who have received experimental vaccines or other immune therapies should be
             discussed with the medical monitor to confirm eligibility

          -  Untreated central nervous system (CNS) metastases or CNS metastases that have
             progressed

          -  Subjects with any active or inactive autoimmune process

          -  Evidence of interstitial lung disease or active, noninfectious pneumonitis

          -  Subjects with any active or inactive autoimmune process

          -  Ocular MEL